Bilah Samping Artikel

Telah diserahkan
July 12, 2024
Diterbitkan
June 30, 2024
Unduh
pdf (English)
Statistik
Baca Penghitung : 167 Unduh : 264

Isi Artikel Utama

Abstrak

Dengue fever is a disease caused by the dengue virus (DENV) which often becomes a problem for public health in the world with approximately 390 million cases of infection. The lack of specific antiviral therapy for DENV is a driving force for the development of a dengue vaccine as a strategy to fight the DENV virus. This review discusses the development of dengue vaccines and makes effectivity comparisons with dengue vaccines that have been developed such as Dengvaxia, TV003/TV005, and DENVax to know the current status of the development of these vaccines.


Keywords : Dengue fever, Dengue Virus, vaccines, development, effectivity

Rincian Artikel

Lisensi

Hak Cipta (c) 2024 Tisa Aulia

Creative Commons License

Artikel ini berlisensiCreative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Cara Mengutip
Aulia, T. (2024). LITERATURE REVIEW: KAJIAN EFEKTIVITAS PERKEMBANGAN VAKSIN VIRUS DENGUE MASA KINI. JURNAL KEDOKTERAN RAFLESIA, 10(1), 46–52. https://doi.org/10.33369/juke.v10i1.35777
Unduh Sitasi
Endnote/Zotero/Mendeley (RIS)
BibTeX

Referensi

  1. Abbas, A. K., Lichtman, A. H., & Pillai, S. (2012). Cellular and Molecular Immunology (7th ed.). Elsevier
  2. Saunders.
  3. Akter, R., Tasneem, F., Das, S., Soma, M. A., Georgakopoulos-Soares, I., Juthi, R. T., & Sazed, S. A.
  4. (2024). Approaches of dengue control: vaccine strategies and future aspects. In Frontiers in
  5. Immunology (Vol. 15). Frontiers Media SA. https://doi.org/10.3389/fimmu.2024.1362780
  6. Foucambert, P., Esbrand, F. D., Zafar, S., Panthangi, V., Cyril Kurupp, A. R., Raju, A., Luthra, G.,
  7. Shahbaz, M., Almatooq, H., & Khan, S. (2022). Efficacy of Dengue Vaccines in the Prevention of
  8. Severe Dengue in Children: A Systematic Review. Cureus, 14(9), e28916.
  9. https://doi.org/10.7759/cureus.28916
  10. Harapan, H., Michie, A., Sasmono, R. T., & Imrie, A. (2020). Dengue: A Minireview. Viruses, 12(8).
  11. https://doi.org/10.3390/v12080829
  12. Khetarpal, N., & Khanna, I. (2016). Dengue Fever: Causes, Complications, and Vaccine Strategies.
  13. Journal of Immunology Research, 2016, 1–14. https://doi.org/10.1155/2016/6803098
  14. Kuhn, R. J., Zhang, W., Rossmann, M. G., Pletnev, S. V, Corver, J., Lenches, E., Jones, C. T.,
  15. Mukhopadhyay, S., Chipman, P. R., Strauss, E. G., Baker, T. S., & Strauss, J. H. (2002). Structure
  16. of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell, 108(5), 717–
  17. https://doi.org/10.1016/s0092-8674(02)00660-8
  18. Laydon, D. J., Dorigatti, I., Hinsley, W. R., Nedjati-Gilani, G., Coudeville, L., & Ferguson, N. M. (2021).
  19. Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of
  20. individual-level phase III data. ELife, 10. https://doi.org/10.7554/eLife.65131
  21. Ma, E., & Cheng, G. (2022). Host immunity and vaccine development against Dengue virus. Infectious
  22. Medicine, 1(1), 50–58. https://doi.org/10.1016/j.imj.2021.12.003
  23. Marimuthu, P., & Ravinder, J. R. (2016). Trends in clinical trials of dengue vaccine. Perspectives in
  24. Clinical Research, 7(4), 161–164. https://doi.org/10.4103/2229-3485.192035
  25. Murugesan, A., & Manoharan, M. (2020). Dengue Virus. In Emerging and Reemerging Viral Pathogens
  26. (pp. 281–359). Elsevier. https://doi.org/10.1016/B978-0-12-819400-3.00016-8
  27. Nanaware, N., Banerjee, A., Mullick Bagchi, S., Bagchi, P., & Mukherjee, A. (2021). Dengue Virus
  28. Infection: A Tale of Viral Exploitations and Host Responses. Viruses, 13(10).
  29. https://doi.org/10.3390/v13101967
  30. Nugraheni, E., Rizqoh, D., & Sundari, M. (2023). Manifestasi Klinis Demam Berdarah Dengue (DBD).
  31. Jurnal Kedokteran Dan Kesehatan : Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya,
  32. (3), 267–274. https://doi.org/10.32539/jkk.v10i3.21425
  33. Thomas, S. J., & Yoon, I. K. (2019). A review of Dengvaxia®: development to deployment. Human
  34. Vaccines and Immunotherapeutics, 15(10), 2295–2314.
  35. https://doi.org/10.1080/21645515.2019.1658503
  36. Wilder-Smith, A. (2022). Dengue vaccine development: challenges and prospects. Current Opinion in
  37. Infectious Diseases, 35(5), 390–396. https://doi.org/10.1097/QCO.0000000000000871